

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

The American Society of Breast Surgeons 2021 Virtual Annual Meeting April 29 – May 2, 2021

Policies and standards of The American Society of Breast Surgeons (ASBrS) and the Accreditation Council for Continuing Medical Education (ACCME) require that committees, speakers (speakers, moderators, discussants, and workshop faculty), planners, consultants, and staff for continuing medical education activities to disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

The ACCME defines a “commercial interest” as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.” It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME defines “financial relationships” as those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (eg, stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

The ACCME considers “relevant” financial relationships are financial relationships in any amount, which occurred in the twelve-month period preceding the time that an individual was asked to assume a role controlling content of a CME activity, and which relate to the content of the educational activity, causing a conflict of interest.

When an individual’s interests are aligned with those of a commercial interest, the interests of the individual are in ‘conflict’ with the interests of the public. The ACCME considers financial relationships to create actual conflicts of interest in CME when individuals have both a financial relationship with a commercial interest **and** the opportunity to affect the content of CME about the products or services of that commercial interest. The potential for maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias.

In addition, ASBrS also focuses on relevant non-financial/strategic business relationships or partnerships occurring within the twelve-month period preceding the time that an individual was asked to assume a role controlling content of a CME activity. Within this timeframe, any relationships or partnerships that have the potential to cloud objectivity and foster institutional loyalty must be disclosed regardless of whether a financial component exists. ASBrS considers nonfinancial business relationships or partnerships of the person involved in the CME activity to include those of a spouse or partner.

Therefore, it is mandatory that all committees, speakers, planners, consultants, and staff involved in the planning, implementation, and evaluation of the annual meeting complete disclosure forms. Members of the committees, consultants, and staff were required to disclose *all financial and non-financial/strategic business relationships as it pertains to their applicable roles* and speakers were required to disclose *any financial and non-financial/strategic business relationships as it pertains to the content of their presentation or participation of the CME activity*.

The American Society of Breast Surgeons is required to manage any reported conflict and eliminate the potential for bias during the activity. The committee members, speakers, planners, consultants, and staff listed below were contacted and any conflicts indicated have been managed to our satisfaction. However, if you perceive a bias during a session, please report the circumstances on the evaluation form.

All relevant financial or non-financial/strategic business relationships or partnerships with ACCME-defined commercial interests are disclosed to learners before start of the CME activity in accordance with ACCME standards. Additionally, participants with no relevant commercial relationship(s) must inform learners that no relevant commercial relationship(s) exist before the start of the CME activity.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow members of the audience to form their own judgments regarding the presentation.

Please note we have advised speakers it is their responsibility to also disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The following individuals and groups have been involved in the planning, implementation, approval, and/or evaluation of this educational activity:

2021 Annual Meeting Committee				
All members were asked to recuse themselves from discussions and decisions where a conflict of interest could occur.				
NAME	NOTHING TO DISCLOSE	DISCLOSURE (All commercial relationships)		
		Company	Received	Role
Katherina Zabicki Calvillo, MD	X			
Sarah Blair, MD	X			
Jill Dietz, MD	X			
Dennis Holmes, MD		Carl Zeiss Meditec	Honoraria	
		Hologic	Consulting Fees	
Brigid Killelea, MD		Up to Date	Royalties	Contributor
Henry Kuerer, MD, PhD		Genentech	Consulting Fee	Advisory Board
		Up to Date, Inc.	Royalties	Editor
		McGraw Hill, Inc.	Royalties	Editor
		NEJM	Editor Fees	Editor
Julie Margenthaler, MD	X			
Walton Taylor, MD		ImpediMed	Consultant Fees	Consultant
		TME	Consultant Fees	Consultant
Shawna Willey, MD		Genentech	Honorarium	Speaker
		Hologic	Honorarium	Advisory Board
		Exact Sciences	Honorarium	Advisory Board
		TransMed7	Honorarium, Stock	Advisory Board, Investor
		Stryker	Honorarium	Advisory Board
		Lumicell	Honorarium	DSMB Member
		Medtronic	Honorarium	Speaker

Board of Directors

All board members were asked to recuse themselves from discussions and decisions where a conflict of interest could occur.

NAME	NOTHING TO DISCLOSE	DISCLOSURE (All commercial relationships)		
		Company	Received	Role
Paul Baron, MD		Myriad Genetics	Honorarium	Speaker, consulting
Michael Berry, MD		TransMed7	Stock	Stock
Peter Blumencranz, MD		Merit Medical Systems, Inc	Honorarium	Consulting
Susan Boolbol, MD		Stryker	Honorarium	
		Exact Sciences	Honorarium	Speaker
Judy Boughey, MD		Lilly	Research Support	Study PI
Jill Dietz, MD (President)	X			
Eric Manahan, MD	X			
Julie Margenthaler	X			
Jane Mendez, MD	X			
Walton Taylor, MD		ImpediMed	Consultant Fees	Consultant
		TME	Consultant Fees	Consultant
Shawna Willey, MD		Genentech	Honorarium	Speaker
		Hologic	Honorarium	Advisory Board
		Exact Sciences	Honorarium	Advisory Board
		TransMed7	Honorarium, Stock	Advisory Board; Investor
		Stryker	Honorarium	Advisory Board
		Lumicell	Honorarium	DSMB Member
		Medtronic	Honorarium	Speaker

CME Committee				
NAME	NOTHING TO DISCLOSE	DISCLOSURE (All commercial relationships)		
		Company	Received	Role
Joseph Contino, MD	X			
Lynn Dengel, MD	X			
Jillian Lloyd, MD	X			
Sarah McLaughlin, MD (Chair)	X			
Ethics Committee (Oversight)				
All committee members were asked to recuse themselves from discussions and decisions where a conflict of interest could occur.				
NAME	NOTHING TO DISCLOSE	DISCLOSURE (All commercial relationships)		
		Company	Received	Role
Emily Bellavance, MD	X			
Cindy Matsen, MD	X			
David Kaufman, MD	X			
Tina Hieken, MD		Genentech	Research Funding	Investigator
Toan Nguyen, MD (Chair)	X			
David Kaufman, MD	X			
Steven Nagel	X			
Caitlin Patten, MD	X			
Terry Sarantou, MD	X			
Alyssa Throckmorton, MD	X			
Paige Teller, MD	X			
Sara Tevis, MD	X			
Lindi VanderWalde, MD	X			

ASBrS Staff				
NAME	NOTHING TO DISCLOSE	DISCLOSURE (All commercial relationships)		
		Company	Received	Role
Marta Boyer, Director, Strategic Partnerships	X			
Christina Lucara, Meetings and Education Coordinator	X			
Laura Randel, Publications Manager	X			
Jane Schuster, Executive Director	X			
Tekoah White, CME Specialist	X			

**22nd Annual Meeting
Speakers/Moderators/Discussants/Presenters Disclosures**

All relevant disclosed relationships have been mitigated by a designated CME Committee Official

Faculty Name	Nothing to Disclose	Disclosed Financial Relationships	Faculty Relationship(s) Relevant to Participation/Presentation – Yes/No	CME Committee Mitigation for Relevant Relationships
Abhishek Chatterjee, MD, MBA, FACS	X			
Abram Recht, MD, FASTRO, FACOS		<ul style="list-style-type: none"> EviCore (CareCore) National Healthcare (radiation oncology benefit management program); Honoraria; Medical Advisory Advisory Board 	No	
Ali Evisar, MD		<ul style="list-style-type: none"> Exact Sciences; Advisory Board 	No	
Amanda Nash, MD	X			
Anees Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS©	X			
Angeleke Saridakis, MD	X			
Ann Partridge, MD, MPH	X			
Anne Peled, MD	X			
Anthony Lucci, MD, FACS	X			
Ava Hosseini, MD	X			
Ayat ElSherif, MD	X			
Ayemoethu Ma, MD	X			
Barbara Smith, MD, PhD	X			
Brigid Killelea, MD		<ul style="list-style-type: none"> Up to Date; Royalties; Contributor 	No	
Chandler Cortina, MD	X			
Courtney Vito, MD	X			
David Brenin, MD, FACS	X			
David Lim, MDCM, MEd, PhD, FRCS	X			
David Ollila, MD, FACS	X			
Dennis Holmes, MD, FACS		<ul style="list-style-type: none"> Carl Zeiss Meditec; Honoraria Hologic; Consulting Fees 	No	
Diana Caragacianu, MD, FACS		<ul style="list-style-type: none"> Medtronic; Honorarium; Speaker 	No	

Elizabeth O'Riordan, MD	X			
Elizabeth Shaughnessy, MD, PhD, FACS		<ul style="list-style-type: none"> • Impedimed; Advisory Board Member • Elucient; Research Grant; Consultant 	No	
Emiel Rutgers, MD, PhD, FRCS	X			
Helen Pass, MD, FACS		<ul style="list-style-type: none"> • Genomic Health; Honorarium; Speaker • Genentech; Honorarium; Speaker 	No	
Henry Kuerer, MD, PhD, FACS		<ul style="list-style-type: none"> • Genentech; Consulting Fee; Advisory Board • Up to Date, Inc.; Royalties; Editor • McGraw Hill, Inc.; Royalties; Editor • NEJM; Editor Fees; Editor 	No	
Hiram Cody III, MD, FACS	X			
J. Michael Dixon, OBE, MD	X			
Jandie Schwartz, DO	X			
Jane Mendez, MD, FACS	X			
Javier Orozco, MD	X			
Jessica Schumacher, PhD, MS	X			
Jill Dietz, MD, MHCM	X			
Judy Boughey, MD, FACS		•Lilly; Research Support; Study PI	No	
Julie Margenthaler, MD, FACS	X			
Kaitlyn Kennard, MD	X			
Kari Kansal, MD, FACS	X			
Kate Pawloski, MD	X			
Katharine Yao, MD, FACS	X			
Katherina Zabicki Calvillo, MD, FACS	X			
Katrina Mitchell, MD, IBCLC, FACS	X			
Kelly Hunt, MD, FACS		<ul style="list-style-type: none"> • Cairn Surgical; Grant/Research Support to institution • Eli Lilly & Company; Grant/Research Support to institution • Lumicell; Grant/Research Support to institution • OncoNano; Grant/Research Support to institution • Armada; Honorarium; Advisory 		

		Committee/Board • Merck & Co.; Honorarium; Advisory Committee/Board	No	
Kirithiga Ramalingam, MD	X			
Lee Wilke, MD, FACS		•Elucent Medical; Minority Stock Owner (<5%) and travel expenses to the company location in MN; Founder •Perimeter Medical; Per patient reimbursement for clinical trial; PI of Institutional Clinical Trial	No	
Leisha Elmore, MD, MPHS	X			
Mahmoud El-Tamer, MD, FACS	X			
Martha Kedrzycki, MD	X			
Melvin Silverstein, MD, FACS	X			
Nirav Savalia, MD	X			
Nur Amalina Che Bakri	X			
Pat Whitworth, MD, FACS		•Targeted Medical Education; Stock, Travel, Expenses •MedNeon; Stock; Research Funding •Puma Technology; Honoraria •Impedimed; Consulting/Advisory Role •Prelude Therapeutics; Consulting/Advisory Role; Consultant Fees, Research Funding •Beckton Dickinson; Consulting/Advisory Role •Agendia; Research Funding; PI	Yes	Peer review of content by persons without relevant financial relationships
Peter Beitsch, MD, FACS		•TME; Ownership Interest; Board of Directors	No	
Rakesh Patel, MD		•Varian Medical; Consulting Fees, honoraria; Consulting, speaker •TME; Ownership interests; Board Member	No	
Richard Fine, MD	X			
Roshni Rao, MD	X			
Sara Blair, MD, FACS	X			
Stephanie Valente, DO, FACS		• Impedimed; Advisory Board Member/Speaker • Pacira; Advisory Board Member/Speaker	No	
Susan Boolbol, MD, FACS		• Stryker; Honorarium • Exact Sciences; Honorarium; Speaker	No	
Swati Kulkarni, MD	X			

Tiffany Traina, MD		<ul style="list-style-type: none"> • Honorarium- Speakers Bureau: Genentech/Roche, Pfizer, AstraZeneca, Merck, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol-Myers Squibb, Athenex, Aduro-Biotech, Daiichi Sankyo, Ionis Pharmaceuticals, Seattle Genetics, Eisai, Immunomedics • Honorarium – Speaker: Roche/Genentech • Research Funding (paid to institution) - Principal Investigator: Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharm, Immunomedics, Genentech/Roche, Daiichi, Carrick Pharm 	No	
W. Fraser Symmans, MD		<ul style="list-style-type: none"> • Delphi Diagnostics; Founder shares, patent application for prediction of sensitivity to endocrine therapy; Scientific Advisor 	No	
Walton Taylor, MD, FACS	X			